Clovis Oncology Inc (NASDAQ:CLVS) price target lowered to $28.00 by SunTrust Banks

Clovis Oncology Inc (NASDAQ:CLVS) price target lowered to $28.00 by SunTrust Banks

Apr 15, 2019 (Market Exclusive via COMTEX) —

Analyst Ratings For Clovis Oncology Inc (NASDAQ:CLVS)

Today, SunTrust Banks lowered its price target on Clovis Oncology Inc (NASDAQ:CLVS) to $28.00 per share.

There are 8 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Clovis Oncology Inc (NASDAQ:CLVS) is Buy with a consensus target price of $42.75 per share, a potential 82.07% upside.

Some recent analyst ratings include

4/14/2019-Clovis Oncology Inc (NASDAQ:CLVS) had its Neutral rating reiterated by Piper Jaffray Companies with a $21.00 price target 4/7/2019-Clovis Oncology Inc (NASDAQ:CLVS) had its Hold rating reiterated by JPMorgan Chase & Co. 12/11/2018-Clovis Oncology Inc (NASDAQ:CLVS) had its Buy rating reiterated by Gabelli 12/4/2018-Clovis Oncology Inc (NASDAQ:CLVS) gets upgraded to Outperform by Leerink Swann On 3/20/2019 Lindsey Rolfe, Insider, sold 1,729 with an average share price of $26.13 per share and the total transaction amounting to $45,178.77. On 3/14/2019 James C Blair, Director, sold 17,056 with an average share price of $27.79 per share and the total transaction amounting to $473,986.24. On 3/5/2019 Lindsey Rolfe, Insider, sold 1,731 with an average share price of $29.29 per share and the total transaction amounting to $50,700.99. On 2/27/2019 Daniel W Muehl, Insider, sold 266 with an average share price of $25.90 per share and the total transaction amounting to $6,889.40. On 12/20/2018 Lindsey Rolfe, Insider, sold 1,728 with an average share price of $17.72 per share and the total transaction amounting to $30,620.16. On 12/4/2018 Lindsey Rolfe, Insider, sold 284 with an average share price of $21.23 per share and the total transaction amounting to $6,029.32. On 4/9/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $60.02

Read More Here...

Bookmark the permalink.